Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- DPJ’s Proposal on 5-Year Innovation Strategy Calls for Subsidies to Reduce Consultation, Review Fees
June 4, 2012
- PAFSC’s 2nd Committee Recommends Approval for Pfizer Japan’s Axitinib
June 4, 2012
- MHLW Announces Addition of 5 APIs/8 Products to NHI Price List
June 1, 2012
- Cost-Effective Assessments “Not Appropriate” for Everything: MED Director Suzuki
May 31, 2012
- DPJ Proposal to Amend PAL Would Mandate Reporting of Package Inserts
May 31, 2012
- Specific Targets for New 5-Year Clinical Trial Activation Plan Expected by Late August
May 31, 2012
- Nakajima of HPB Calls on Kampo Association to Collect Data, Make Case for Favorable Re-Pricing
May 30, 2012
- MHLW Adds 8 APIs/10 Products Including Xalkori to NHI Price List
May 30, 2012
- MHLW Sets Up Office for Promotion of Medical Innovation to Realize New 5-Year Strategy
May 29, 2012
- MHLW Selects 5 Additional Clinical Research Core Hospitals
May 29, 2012
- AZ, Government Not Accountable in Iressa Appeal, Osaka High Court
May 29, 2012
- Chicken Pox, Mumps, and Adult Pneumococcal Vaccines to Be Added to Routine Vaccination Programs in FY2014 “at Earliest”: Dr Niki of DPJ
May 28, 2012
- CSIMC Expert Subcommittee Holds 1st Meeting on Cost-Effective Assessment; Members Urge Caution
May 25, 2012
- CSIMC Approves Listing for 8 APIs/10 Products; Peak Sales of Xalkori Expected to Reach 11.2 Billion Yen
May 25, 2012
- DPJ’s PAL Subcommittee Calls for Mandatory Submission of Package Inserts
May 24, 2012
- DPJ’s Committee Prepares Submission of Lawmaker-Initiated Bill to Create Third-Party Organization
May 24, 2012
- CSIMC Recommends NHI Price Listing for 8 APIs/10 Products Including Xalkori, Poteligeo
May 24, 2012
- Working Group to Set Specific Targets for 5-Year Clinical Research/Trial Activation Plan
May 22, 2012
- 1st Committee to Discuss 5 Items Including Add’l Indication of Fibromyalgia for Lyrica on June 1
May 22, 2012
- Gov’t to Form 3 Strategic Councils for Science & Technology Policy, with Its 1st Meeting for Medical Care on May 25
May 22, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…